Weimi Bio Completes Over RMB 100 Million Series B Financing Led by CICC Capital with Continued Participation from Existing Investor Med-Fine Capital
VCBeat (WeChat ID: vcbeat) has learned that Guangzhou Weimi Bio-Tech Co., Ltd. (“Weimi Bio”) announced in early October that it had completed its Series B financing round, with the amount exceeding RMB 100 million. The round was led by CICC Qide Fund, under CICC Capital, and co-invested by Mifang Capital, Chuangyu Investment, and Jiahong Medical.
Guangzhou Weimi Bio-Tech Co., Ltd. was established in September 2013 and is located in the South China New Material Innovation Park within Guangzhou Science City. As a national high-tech enterprise, it integrates research and development, production, and sales, dedicated to the integrated development of in vitro diagnostics (IVD) technology and industry. Weimi Bio has assembled a team of experts and technical professionals spanning multiple fields, including biotechnology, genetics, microbiology, immunology, and medical laboratory science, and has established a comprehensive modern corporate management system. The company has been awarded the Major Special Project for Industry-Academia-Research Collaborative Innovation by Guangzhou Municipality and recognized as one of the Top 100 Innovative Enterprises at the China Science and Technology Innovation Summit. In 2021, it was selected as an enterprise under cultivation for Guangzhou’s “Specialized, Refined, Differential, and Innovative” Private Enterprise Support Program. Due to its outstanding performance in the field of neuro-autoimmunity, Weimi Bio was designated by the Guangdong Provincial Department of Science and Technology as the Guangdong Engineering Center for Multiplex Fluorescence Precision Diagnosis of Neuroimmune Diseases.
“A Momentum of One Meter Begins with the Micron.” With the support of industrial investors Jinhe Capital and Mifang Capital, Weimi Bio has maintained high R&D investment for eight consecutive years, rapidly establishing a strategic layout of “One Body, Two Wings” encompassing eight technology platforms. The “Two Wings” consist of two high-end platforms: neuro-autoimmunity and flow fluorescence. The “One Body” comprises six conventional platforms: acridinium ester chemiluminescence, biochemistry, time-resolved fluorescence quantification, indirect immunofluorescence, enzyme immunoassay, and colloidal gold. Weimi Bio places particular emphasis on developing exclusive new products with significant clinical diagnostic value. Its product portfolio primarily covers pathogenic microorganism detection, inflammation detection, prenatal screening, cardiovascular and cerebrovascular disease detection, and tumor detection, serving all hospital departments. Currently, the company has obtained approval for market launch of over 300 products, including several exclusive new offerings.
Mr. Wang Tao, Founder and Chairman of Weimi BioWith over 20 years of industry experience in clinical medicine, market operations, and team management, specializing in strategic planning and resource integration.Chairman Wang Tao“We extend our gratitude to investors such as CICC Capital, Jinhe Capital, Mifang Capital, Chuangyu Investment, and Jiahong Medical for their support and encouragement of Weimi Bio-Tech. With financial and industrial investors as our dual drivers—‘Jin’ (gold) forming the blade and ‘Mi’ (power) shaping the square—we will adhere to our ‘One Body, Two Wings’ strategic layout, accelerate development, and strive for new heights.” Chairman Wang Tao believes that the broader healthcare sector is poised for humanity’s Fifth Industrial Revolution. As the IVD industry is closely intertwined with human health, we must steadfastly uphold the conviction of “serving the people and the populace,” contributing our humble efforts to the localization of China’s IVD industry.
Liang Ying, Managing Director of CICC Capital and Head of the CICC Qide Fund, as the lead investor in Series B financingstating: “China’s in vitro diagnostics (IVD) market is experiencing rapid growth, with substantial room for further substitution of imported products by domestically produced ones. The management team of Guangzhou Weimi Bio-Tech Co., Ltd. combines keen market insights with outstanding strategic planning capabilities. We are optimistic about the company’s product portfolio and leading position in the fields of neuro-autoimmunity and flow fluorescence platforms. Leveraging its ‘one core, two wings’ multi-platform system, along with a comprehensive sales and marketing network, we believe the company is poised for rapid, high-quality development.”
Hao Bixi, Founder of Jinhe Capital, Lead Investor in Series A Financingstated: “As the first industrial investment institution to lead the investment in Weimi Bio-Tech, Jinhe Capital has witnessed its tenfold growth. We remain bullish on Weimi’s ‘one core, two wings’ product layout and its dual-engine drive of R&D and marketing. Jinhe Capital will fully leverage its industrial resource advantages to continuously empower Weimi Bio-Tech, helping the company stay at the forefront of the IVD industry.”
Li Shanbing, Partner at Mifang Capital“Micron Bio’s management team has consistently prioritized breakthroughs in core technologies, demonstrating robust innovation capabilities and comprehensive expertise. Mifang Capital is highly optimistic about the technological accumulation Micron Bio has built over the years in the in vitro diagnostics (IVD) industry and will continue to support the company, working together to advance the development of the IVD sector.”
He Tao, Chairman of the Investment Committee at Chuangyu InvestmentIt stated: “Weimi Bio-Tech’s management team possesses profound expertise and unique insights in the IVD sector. Against the backdrop of population aging and the overarching trend toward domestication, Chuangyu Investment is optimistic about Weimi Bio-Tech’s strategic layout in this field, as well as its high-quality development driven by the dual engines of R&D and marketing.”
Weimi Bio-Tech is a high-tech biomedical enterprise dedicated to novel in vitro diagnostic (IVD) technologies, integrating research and development (R&D), production, and sales. The company has established robust R&D and marketing teams and built a mature IVD reagent development platform, featuring a strategic design of “one core with two wings” encompassing eight technology platforms. Its product portfolio primarily focuses on pathogenic microorganism detection, inflammation testing, prenatal screening, cardiovascular and cerebrovascular disease testing, and tumor detection.
CICC Qide (Xiamen) Innovative Biopharmaceutical Equity Investment Fund (hereinafter referred to as the “CICC Qide Fund”) is an equity investment fund under CICC Capital Management Co., Ltd. (hereinafter referred to as “CICC Capital”) that focuses on innovative pharmaceuticals, marking a significant breakthrough in CICC Capital’s strategic layout within the biopharmaceutical industry. Leveraging its strong performance track record, brand reputation, and investment management capabilities, the CICC Qide Fund has gained recognition and support from numerous renowned fund-of-funds, institutional investors, listed companies, and clients of CICC Wealth Management. It completed oversubscribed fundraising in a relatively short period, becoming one of the largest RMB-denominated biopharmaceutical funds in terms of scale over the past two years.
Jinhe Capital is an investment firm focused on the healthcare and medical sector. Its fund manager boasts over 20 years of experience in the medical industry and has successfully built China’s largest third-party medical laboratory. The investment team possesses extensive experience in healthcare investments, and its inaugural fund secured backing from a well-known domestic fund of funds. Jinhe Capital will make strategic deep investments in in vitro diagnostics (IVD) to build an industrial ecosystem, committed to leveraging the synergy between industry and capital to cultivate enterprises with international competitiveness.
Med-Fine Capital is a specialized investment fund focused on the pharmaceutical, healthcare, and life sciences sectors. The fund’s team boasts extensive industry background, abundant sector resources, and professional investment expertise in pharmaceuticals and healthcare. To date, the fund has completed investments in more than 50 emerging companies, including TianGuangShi, Hanyu Medical, Zhanrong Pharma, InnoMicro, HeartCon Medical, Lingke Pharma, Ansong Technology, Libang Pharma, Pengli Biologics, Colibrigen, Yehui Pharma, Anrui Biologics, Zhongyi Anke, and CAS Gene.
Adhering to the philosophy of “focusing on pharmaceuticals, healthcare, and life sciences, leveraging capital value, and rewarding trust,” Mifang Capital is committed to becoming a professional pharmaceutical investment fund with an open-platform model, outstanding international competitiveness, and far-reaching reputation.
Chuangyu Investment is positioned as a boutique investment bank. Leveraging its deep footprint across multiple industries, including biopharmaceuticals, intelligent manufacturing, and energy conservation and environmental protection, the firm has achieved remarkable results and received numerous accolades, such as “Top 10 Emerging Investment Institutions in China for 2020” and “Most Promising Investment Institution in China for 2020” by Financing China. Over the past year, six of its portfolio companies have successfully gone public or passed regulatory review, two have achieved exit, and three have filed for initial public offerings (IPOs).